CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.